The effect of age on the clearance (CL) of therapeutic proteins has not been explored extensively in pediatric subjects. Recently, resting energy expenditure (REE) has been proposed to link age-dependent CL with developmental changes. Allometric relationship was explored to assess the impact of REE on the CL of therapeutic proteins in pediatric subjects. The CL of a therapeutic protein estimated from allometric scaling using REE was approximately 2-fold higher than that using body weight (BW) in younger children. For some monoclonal antibodies, REE was a better predictor than BW to estimate CL in pediatric subjects. Overall results suggest that the relationship of CL with REE and its clinical importance in therapeutic proteins need to be investigated further for pediatric subjects.

Keywords:
Pediatrics, Therapeutic proteins, Clearance, Resting energy expenditure
1.
Xu Z, Davis HM, Zhou H: Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther 2013;137:225-247.
2.
Mould DR, Green B: Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010;24:23-39.
3.
Mould DR, Sweeney KR: The pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007;10:84-96.
4.
Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-2668.
5.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507.
6.
Grimm HP: Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 2009;36:407-420.
7.
Ling J, Zhou H, Jiao Q, Davis HM: Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009;49:1382-1402.
8.
Kearns GL, Abdel-Rahman SM, Alander SW, et al: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
9.
Mahmood I: Pharmacokinetic considerations in designing pediatric studies of proteins, antibodies, and plasma-derived products. Am J Ther 2012, Epub ahead of print.
10.
Goldman JL, Davis HM, Zhou H, Kearns GL: Infliximab clearance in children: potential association with resting energy expenditure. Ann Paediatr Rheum 2012;1:120-125.
11.
Dirks NL, Meibohm B: Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:633-659.
12.
Kaplan AS, Zemel BS, Neiswender KM, Stallings VA: Resting energy expenditure in clinical pediatrics: measured versus prediction equations. J Pediatr 1995;127:200-205.
13.
CDC: Percentile Data Files with LMS Values. August 4, 2009.
14.
Hocker B, Kovarik JM, Daniel V, et al: Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008;86:1234-1240.
15.
Pescovitz MD, Knechtle S, Alexander SR, et al: Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant 2008;12:447-455.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.